- Home
- SNY vs BMY Comparison
SNY vs BMY Comparison
Compare SNY & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNY | BMY |
|---|---|---|
| Founded | 1994 | 1887 |
| Country | France | United States |
| Employees | 74846 | 32500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.3B | 123.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SNY | BMY |
|---|---|---|
| Price | $46.82 | $58.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 16 |
| Target Price | $58.00 | ★ $61.81 |
| AVG Volume (30 Days) | 3.7M | ★ 9.6M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | 3.43% | ★ 4.24% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.01 | N/A |
| Revenue Next Year | $5.80 | N/A |
| P/E Ratio | ★ $6.14 | $17.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.32 | $42.52 |
| 52 Week High | $55.77 | $62.89 |
Technical Indicators
Market Signals| Indicator | SNY | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 58.78 | 46.27 |
| Support Level | $45.20 | $53.88 |
| Resistance Level | $48.97 | $62.47 |
| Average True Range (ATR) | 0.76 | 1.18 |
| MACD | 0.37 | -0.20 |
| Stochastic Oscillator | 77.94 | 43.40 |
Price Performance
Historical ComparisonAbout SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.